MPE activities

 
MPE Annual General Meeting (AGM) 2020
Amsterdam, The Netherlands. 6-8 March 2020
 
  

motionmailapp.com

MPE activities

The agenda of the AGM 2020 is now available

Once a year Myeloma Patients Europe (MPE) holds its Annual General Meeting (Masterclass and AGM General Assembly). All MPE members and sponsors are invited to this event which includes a one-and-a-half day Masterclass to provide training to MPE members with scientific sessions, given by the most important specialists in Europe, and advocacy sessions. Check the preliminary agenda of the Masterclass in the link below and register now.
 

Myeloma ASH 2019 preview

More than 900 myeloma abstracts (posters and oral sessions) will be presented in the largest world congress of hematology: the America Society of Hematology (ASH) Annual Meeting 2019 that will be held from 7 to 10 December 2019 in Orlando, Florida, USA. Read this article to find out what topics MPE anticipates the myeloma and AL amyloidosis highlights will be focused on.
 

New round of Myeloma-CABs

MPE is holding another round of Myeloma Community Advisory Board (Myeloma-CAB) meetings, from 17 – 18 November in Munich, Germany. In preparation for this set of meetings, the members of the Myeloma-CAB received excellent training from João Carapinha on behalf of Carapinha & Company. This educational session was focused on pricing and reimbursement challenges related to myeloma. Find here more information about the MPE myeloma CABs in the link below.
 

Survey on myeloma patient information needs is now open in Hungary

We keep gathering feedback about myeloma patients information needs. Now, our survey is open in Hungary too. If you are a myeloma patient who has received at least one prior treatment or is currently on their first treatment and you live in Austria, Finland, France, Germany, Hungary, The Netherlands, Poland, Romania, Sweden, or the UK, help us by completing this survey. Find the the country-specific survey links and translations in all relevant languages in the link below.

News

 

Positive results of ixazomib as first line maintenance therapy
 

The randomized, placebo-controlled, double-blind Phase 3 clinical trial TOURMALINE-MM4 showed significant improvement in Progression-Free Survival (PFS) of Ixazomib (commercialised by Takeda as Ninlaro) as first line maintenance therapy versus placebo in adult myeloma patients not treated with stem cell transplantation. This clinical trial is the first industry sponsored phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting.
 

If you are an MPE member and you would like to share your activities in this e-bulleting, please contact Ana Vallejo: vallejo@mpeurope.org.

 
ASH 2019 Annual Meeting
Orlando, 7-10 December
The American Society of Hematology (ASH) Annual Meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.
More information

MPE AGM 2020
Amsterdam, 6-8 March
Once a year MPE holds its Annual General Meeting (Masterclass and AGM General Assembly). All MPE members and sponsors are invited to this event which includes a one-and-a-half day Masterclass to provide training to MPE members with scientific sessions, given by the most important specialists in Europe, and advocacy sessions.
More information
 

Would you like to get involved in MPE patient-focused activities and research? Find more information in this link and complete the form